Inhaled Fluticasone Propionate by Diskus in the Treatment of Asthma: A Comparison of the Efficacy of the Same Nominal Dose Given Either Once or Twice a Day

Chest

Volumn 124, Issue 4, 2003, Pages 1584-1593

  Purucker, Mary E ^a   Rosebraugh, Curtis J ^a,b   Zhou, Feng ^a   Meyer, Robert J ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b Div of Over The Counter Drug Prod   (United States)

Author keywords

Asthma; Diskus; Dose regimen; Flovent; Fluticasone propionate; Multidose powder inhaler; Pediatric study

Indexed keywords

FLUTICASONE PROPIONATE;

ASTHMA; CLINICAL TRIAL; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HUMAN; MAINTENANCE THERAPY; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0142074237     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.124.4.1584     Document Type: Article

References (15)

1. Nathan RA, Li JTC, Finn A, et al. A dose-ranging study of fluticasone propionate administered once daily via multidose powder inhaler to patients with moderate asthma. Chest 2000; 118:296-302
2. ZuWallack RZ, Adelglass J, Clifford DP, et al. Long-term efficacy and safety of fluticasone propionate powder administered once or twice daily via inhaler to patients with moderate asthma. Chest 2000; 118:303-312
3. Berger WE, Ford LB, Mahr T, et al. Efficacy and safety of fluticasone propionate 250 ug administered once daily in patients with persistent asthma treated with or without inhaled corticosteroids. Ann Allergy Asthma Immunol 2002; 89:393-399
4. Juniper EF, Guyatt G, Ferrie P, et al. Measuring quality of life in asthma. Am Rev Respir Dis 1993; 147:832-838
5. National Asthma Education and Prevention Program. Expert panel report 2: guidelines for the diagnosis and management of asthma. Bethesda, MD: US Dept of Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute; February 1997; Publication No. 97-4051
6. Crapo RO, Morris AH, Gardner RM. Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis 1981; 123:659-664
7. Polgar G, Promadhat V. Pulmonary function testing in children: techniques and standards. Philadelphia, PA: WB Saunders, 1971; 12-17
8. Cumming RG, Mitchell P, Leeder SR. Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med 1997; 337:8-14
9. Israel E, Banerjee TR, Fitzmaurice GM, et al. Effects of inhaled glucocorticoids on bone density in premenopausal women. N Engl J Med 2001; 345:941-947
10. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med 1999; 159:941-955
11. Purucker M, Malozowski S. Inhaled cortcosteroids and growth velocity in children with asthma. J Pediatr 1999; 318:1355
12. Lipworth BJ. Fluticasone and cortisol measurements. Chest 2001; 119:984-985
13. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry: E10 choice of control group and related issues in clinical trials. Available at: http:// www.fda.gov/cder/guidance/4155fnl.htm. Accessed September 19, 2003
14. Temple R, Ellenberg SS. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Ann Intern Med 2000; 133:455-463
15. Mann E, Eliasson O, Patel K, et al. A comparison of the effects of bid and qid dosing on compliance with inhaled flunisolide. Chest 1992; 101:496-499 (CHEST 2003; 124:1594-1597)